-
Dr. Tao Sun: Efficacy and Safety of the Triple Combination of Penpulimab, Anlotinib, and Nab-Paclitaxel as First-Line Therapy for Advanced TNBC
Among breast cancer subtypes, triple-negative breast cancer (TNBC) has long been a clinical challenge due to its high malignancy and poor prognosis. Traditional therapies for advanced TNBC often yield suboptimal results, but the rise of immunotherapy has brought new hope to patients.
-
AASLD Expert Interview丨Dr. Lungen Lu Shares New Advances in MASLD Research
Hepatology Digest: What studies did you find most noteworthy at this year’s conference? Could you briefly introduce these studies and their clinical significance? Dr. Lungen Lu: It’s an honor to…
-
AASLD 2024 | Dr. Hong Tang’s Team Advances HBV, MASLD, Liver Fibrosis, HCC, and ACLF Research
Part 1: Hepatitis B Imatinib Promotes HBV Reactivation via Oxidative Stress-Induced Incomplete Autophagy (Poster No. 1242) Imatinib, a landmark drug in molecular targeted cancer therapy, carries a high risk of…
-
Unveiling Highlights from the CAHON Winter Symposium 2024!
On December 6, CAHON brought together a distinguished group of hematology and oncology experts at The University Club Atop Symphony Tower in San Diego, CA. The symposium was a celebration of collaboration, innovation, and mentorship.
-
SABCS 2024 | Prof. Yongmei Yin Connects with Prof. Qiang Liu: Key Findings from the Conference’s Final Day on Immunotherapy Advances
The 47th San Antonio Breast Cancer Symposium (SABCS), held from December 10–13, 2024, in San Antonio, USA, showcased the latest research, clinical practices, and technological innovations in breast cancer. In this special installment of the “Highlights Series,” hosted by Prof. Yongmei Yin of Jiangsu Provincial People’s Hospital, Prof. Qiang Liu from the Sun Yat-sen Memorial…
-
Dr. Jun Zhou: Lessons from 29 Protocol Revisions in the CheckMate649 Study – A Blueprint for Clinical Trial Design in Immunotherapy
To advance the standard of care for gastrointestinal cancers in China and share the latest developments and insights, the “2024 CSCO Workshop on Standardized Diagnosis and Treatment of Gastrointestinal Cancers,” co-hosted by the Chinese Society of Clinical Oncology (CSCO), the Beijing Xisike Clinical Oncology Research Foundation, and the Hangzhou Oriental Clinical Oncology Research Center, took…
-
SABCS 2024 | Dr. Baoliang Guo: The Dilemma of Immediate vs. Delayed Surgery in Operable Breast Cancer Patients Aged 70+
With the global aging population, treatment strategies for breast cancer patients over 70 years old have garnered increasing attention. At the 2024 SABCS conference, a patient-level meta-analysis conducted by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) addressed the impact of immediate versus delayed surgery on outcomes in operable breast cancer patients aged 70+ (Abstract…
-
AASLD 2024丨Dr. Hui Wang’s Team: Serum HBV RNA and HBcrAg as Predictors of Low-Level Viremia in CHB Patients Treated with Nucleos(t)ide Analogs
This research is the first to conduct dynamic monitoring of HBV RNA and HBcrAg in CHB patients treated with NAs. The results revealed that compared to patients who achieved sustained…
Connecting Medical Expertise through Media